ScreenerHero

LKFT LAKEFRONT BIOTHERAPEUTICS

AMS · NL · Healthcare · Biotechnology · lakefrontbio.com
25.66EUR-0.23%Mkt Cap: 1.83B $P/E: 2.84

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap1.83B USD
Enterprise Value-596.17M USD
Revenue (TTM)1.08B USD
Gross Profit1.18B USD
Net Income (TTM)348.79M USD
Revenue/Share15.03 EUR
Last Price25.66 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINBE0003818359
Valuation
P/E (Trailing)2.84
P/E (Forward)-5.18
PEG—
EV/EBITDA-0.96
EV/Revenue-0.55
P/S1.70
P/B0.52
EPS (TTM)9.02
EPS (Forward)-4.95
52W Range
22.3232% of range32.74
52W High32.74 EUR
52W Low22.32 EUR
Profitability
Gross Margin97.33%
Oper. Margin-359.30%
EBITDA Margin57.43%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-81.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-279.84M USD
CapEx (TTM)15.06M USD
FCF Margin13.95%
FCF Yield8.22%
Net Debt-2.43B USD
Net Debt/EBITDA-3.93
Balance Sheet
Debt/Equity0.00
Current Ratio32.84
Quick Ratio32.65
Book Value/Sh49.71 EUR
Cash/Share34.11 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)31.46 EUR
Upside (mean)+22.6%
Target Range19.00 EUR – 44.80 EUR
19.00+22.6% to mean44.80
# Analysts7
Ownership
Shares Out.65.48M
Float23.72M
Insiders25.36%
Institutions43.15%
Technical
SMA 5024.65 (+4.1%)
SMA 20025.90 (-0.9%)
Beta0.12
S&P 52W Chg14.58%
Avg Vol (30d)98.15K
Avg Vol (10d)106.14K
Technical Indicators
RSI (14)53.3
MACD0.4321
MACD Signal0.3874
MACD Hist.+0.0447
BB Upper27.66 EUR
BB Middle25.11 EUR
BB Lower22.56 EUR
BB Width20.28%
ATR (14)0.7766 EUR
Vol Ratio (20d)0.77x